Shares of Phibro Animal Health have fallen more than 25% since the beginning of the year, as the New Jersey company has come under pressure from the changing regulatory environment for antibiotics used in food production. Those pressures were evident in Phibro’s fourth-quarter and fiscal 2016 results.
